Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
No idea what is going on with the share price but you've got to take confidence from the HNWI's, these wouldn't throw good money after bad, they've seen the investments and whilst dropped from the 8p+ they are still wanting to give Sareum more money.
Sareum has a history of only raising what it needs, so I'm confident that something will give soon. We've already been told about a share consolidation so let's just wait and see how they package up, and again if the high net worths are supporting it at 5p then happy days.
5 week PI
https://clinicaltrials.gov/ct2/show/NCT05091723?spons=Theravance+Biopharma&draw=2&rank=2
Hey potnak, I wouldn't think your timescales are correct. Very hard to know when we don't know the indication, but as an example, 8 weeks for a first in human PI targeting COVID, see link below:
https://clinicaltrials.gov/ct2/show/NCT04350736?spons=Theravance+Biopharma&draw=2&rank=8
Study is the same as John has already confirmed, a SAD/MAD study.
1802 PI will be a longer completion I would suspect but let's get the data for 1801 first.
Puzzle to me is why do we need consultants for what should be a simple trial and what Tim and John surely know about. More questions than answers but I don't think your timescales are accurate due to the size of the patient population in the targets we should be going for. Can't use SRA737 as a comparison.
Best regards
Hi HBD, I've used your video link to directly message our chairman on twitter.
Also with a suggestion of hearing from our other BOD members, I believe we have a strong board who can take us further, but we need more from them at this point and leading up to the consolidation.
Great transformational year, yeah I said it - haha, touted by Tim since 2016 but as we know timescales slip and the market is behind. Certainly worth the wait though and the arrival of an institution next year is almost nailed on.
One point to ponder over the period, the use of consultants for trial design and the message from a recent recovery admission.
"Sotrovimab is being provided by GlaxoSmithKline (GSK) and Vir Biotechnology Inc., who developed the treatment. GSK and Vir have no involvement in the study design, conduct, or analysis of the results".
https://www.recoverytrial.net/news/sotrovimab-to-be-investigated-by-the-recovery-trial-as-a-possible-treatment-for-patients-hospitalised-with-covid-19
Are we using consultants as per an AGILE requirement to ensure best interests of both parties..
Lastly, look at this deal...
https://www.fiercebiotech.com/biotech/sanofi-gambles-1b-upfront-preclinical-oncology-biotech-bagging-amunix-for-its-pipeline-t
And are we worth a billion...easily... Market so far behind and that's why we have HNW's lining up and institutions wanting to come onboard, strap yourself in for a 2022 to remember!
Take care everyone.
Chairman has not supported a share consolidation in the past, fees too high and not a lot to gain previously. However, now we are ready for that step up in credibility, I would not have supported a consolidation previously but with HNWIs onboard at premium prices, a strong BOD, tox completed, Sierra funds coming in then we can look forward to 2022 knowing SDC-1801 will be going into humans. With the massive potential of a tyk2 inhibitor Sareum will look very different from what it is now, risk reward for those with cash to burn pretty positive. If COVID can speed up the whole clinical process it makes up for the delays if the past, but let's put them behind us now, toxicology is complete, no more studies, no more tests, no more delays on toxicology, that could have broken this company so the milestone of official completion now pushes this to a very investable company. Will we continue then strategy of license early, that is the debate to be had at BOD level.
Yes I do not like the change, but everything is for a reason and imo that is for the COVID play, existing COVID pill, Molnupiravir, capsule formulation, still in trials and has preorders booked.
Yes we've moved to capsule, has this just brought forward revenue - it'll be for a very good reason and I believe we don't yet know what that actually is but I'm sure it supports the business strategy and importantly, shareholder value.
Indeed Danny, after all it's another value driver in any large pharma, a COVID pill. Look at the money made with the vaccines and we have multiple of those.
Tyk2 proven to be a gene of interest,. Gene study author, Kenneth Baille confirmed on twitter inhibition of tyk2 should be a target, we then proved that with our grant. For that story to end there with only Baracitinib is impossible, allosteric tyk2s don't work on COVID target from what I recall, step forward another with preclinical models to prove it.
Officially finish preclinical and doors will be opening.
Parker retweet of my tweet was a good sign as it means imo he agrees that we are completing preclinical very soon, before 2022 imo. Before the AGM, I'd love to see that.
Few thoughts, this completion could be the catalyst for the next big value driver, a licence on 1801.
Huge support for this licence by existing shareholders but only if the price/deal is right, the board have been consistent with their shareholder value comments, balance between need for cash and later stage more lucrative deal.
Already confirmed that we will.need more cash for the actual clinical trials, suspect this is already prepared from the HNWI's, as why take consultants onboard to design the trial, costs must be accounted for if Sareum are to get the go ahead, as we know they leave no stone unturned.
If you watch the YouTube videos from about 5year ago you'll hear Tim say that you can do a deal at anytime with the right target, now just look at what tyk2 has become, unbelievable.
Personally I'm hoping that the COVID play isn't dead and the consultants and reformulation into capsule are part of the prerequisites to a deal.
If you read about previous M&A in this sector you'll discover that not all deals are simple, Sareum could play this a multitude of ways, sell rights to specific regions and use of clinical data, options for licensor to take worldwide rights at a later stage, I'm hoping they are getting creative as that is a way to protect shareholders into the future development of our compounds, an addition to the board would be welcome in the face of any deal from a large pharma. Pfizer on the spending spree and confirmed on an investor call that they want medical breakthroughs in early stage development, tyk2 can imo be classed as a breakthrough now that FDA approved BMS drug and the amount of disease, including COVID that could be treated.
Pfizer could take 1801 in COVID only, I'm sure we'll all be happy with that, but they know the JAK class very well indeed, recently stopped development of majority of their JAK inhibitors, they will have some amazing in-house expertise in this area now, which lets forgot is still very new in pharma timescales. Breakthrough treatments in multiple disease, instant FDA fast track.
https://www.fiercepharma.com/pharma/abbvie-s-rinvoq-notches-crohn-s-disease-win-amid-class-wide-jak-safety-concerns
A safer drug in this class will become the blockbuster of the year, capsule format should also help with all new assessments by FDA in the future, the more we can disassociate with oral JAK the better, the next gen capsule JAK. Now go and write an article Tim, publishing the toxicology results to the world.
Hoping the company releases a form of RNS to update the market that formal toxicology is complete and results are positive.
If you remember Parker tweeted at the time about a stronger formulation to allow completion, this was then confirmed that it will complete by year end. The fact that we have now got experts onboard (at a cost) to help with the trial design confirms that any toxicology worries should be put to bed.
We normally get an AGM statement from chairman on the day but considering the importance of this completion it warrants its own RNS imo.
Further grant announcement from UKGOV for COVID would also be welcomed, considering its a year since our last grant.
Just look at the market size for a safer inhibitor, Sareum are on the verge here, I'd expect some larger players to take a position in the company on the expectation of improved safety and a nice market share.
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-warns-increased-heart-related-issues-pfizers-arthritis-drug-xeljanz-2021-12-03/
Mentioned a while ago about fundraise questions, if you take a look at Sareum Holdings on companies house you will the various alloted share issues, had a quick look and tried to tie them to the RNS releases, some tally up and some don't for me yet, but I suspect I just can't see the links.
https://find-and-update.company-information.service.gov.uk/company/05147578/filing-history
Some are associated with the salary deferral aswell.
As we know the funds raised are all for preclinical work, we'll be going back to our investors should we choose to take to clinic. I'm confident that the existing investors are able to fund whatever we ask.
We are not listed as presenting at the Edison event in January so imo, we are sorted.
https://www.edisongroup.com/event/open-house-global-healthcare-2021/#
Tim has not allowed them to invest too much too quick for a simple reason, it increases shareholder value by issuing shares when we need the money. That will continue to drive the SP in the right direction. BOD share purchase on any drop and it's blue skies
Hi Citizen,
Yes, all good this end my friend. As Thoth has stated before, the markets and even some pharma are playing catch up, I think we don't really know the value of the patents as for a catalytic Jak inhibitor we are the only one. The lack of competition can point to a few arguments; it's a worthless target, it's too difficult to get selectivity, it's patent protected.
Tim and moreso John is probably one of the most well researched scientists in this field after what is nearly 10years on compound design, the patent he has produced may well have far reaching implications in the design of a further tyk2 inhibitor. The BOD know the value of the patent and that is why imo we haven't licensed it already, as time continues to pass the offers will keep going up.